Novavax, Inc. $NVAX Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC decreased its stake in shares of Novavax, Inc. (NASDAQ:NVAX) by 41.6% during the second quarter, HoldingsChannel reports. The firm owned 81,676 shares of the biopharmaceutical company’s stock after selling 58,151 shares during the quarter. Intech Investment Management LLC’s holdings in Novavax were worth $515,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Park West Asset Management LLC purchased a new stake in shares of Novavax during the first quarter valued at $16,210,000. Jupiter Asset Management Ltd. lifted its position in Novavax by 195.9% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 880,410 shares of the biopharmaceutical company’s stock worth $5,547,000 after acquiring an additional 582,858 shares during the period. Allianz Asset Management GmbH purchased a new stake in Novavax during the 2nd quarter valued at about $3,382,000. Jump Financial LLC acquired a new position in shares of Novavax in the first quarter valued at about $3,280,000. Finally, Nuveen LLC acquired a new position in shares of Novavax in the first quarter valued at about $2,517,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Trading Up 1.1%

Shares of Novavax stock opened at $7.02 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The stock’s 50 day simple moving average is $8.03 and its 200-day simple moving average is $7.60. The stock has a market cap of $1.14 billion, a P/E ratio of 3.08, a P/E/G ratio of 0.12 and a beta of 2.68. Novavax, Inc. has a 1-year low of $5.01 and a 1-year high of $11.55.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The company had revenue of $70.45 million for the quarter, compared to analysts’ expectations of $55.63 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business’s quarterly revenue was down 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.76) EPS. Novavax has set its FY 2025 guidance at EPS. Analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on NVAX shares. JPMorgan Chase & Co. reduced their price target on shares of Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a research report on Tuesday, November 18th. B. Riley reissued a “buy” rating and set a $16.00 target price (down previously from $18.00) on shares of Novavax in a report on Monday, November 10th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a research report on Tuesday. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, TD Cowen reduced their price objective on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $11.25.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.